PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。我们的目的是探讨高龄对抗癫痫药物的药代动力学和代谢的影响。选择老年人和成年男性和女性门诊患者服用苯妥英（PHT或CBZ）作为癫痫的单一疗法将进行评估。患者将接受口服剂量的一部分，作为稳定标记的PHT，在5分钟内静脉给予100mg（仅一次）。稳定标记的PHT没有放射性，并且表现出与未标记的PHT相同的动力学和代谢。血样和尿样将被分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to investigate the effect of advanced age on antiepileptic drug pharmacokinetics and metabolism. Selected elderly and adult male and female ambulant patients taking phenytoin (PHT or CBZ) as monotherapy for epilepsy will be evaluated. The patients will receive a portion of their oral dose of PHT as stable-labeled PHT given intravenously as 100 mg over 5 minutes (one time only). Stable-labeled PHT is NOT radioactive and exhibits the same kinetics and metabolism as unlabeled PHT. Blood samples and urine collections will be analyzed.